Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (Prior IO)
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Panagiotis Konstantinopoulos, MD, PhD
- Target Recruit Count
- 25
- Registration Number
- NCT06518564
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 70
- Registration Number
- NCT06424717
- Locations
- 🇩🇪
Please Contact the Communication Center, Darmstadt, Germany
🇺🇸Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 300
- Registration Number
- NCT06412848
- Locations
- 🇯🇵
Iwate Medical University Hospital, Shiwa-gun, Iwate, Japan
🇯🇵Kagawa University Hospital, Kita-gun, Kagawa, Japan
🇯🇵St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06228066
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 956
- Registration Number
- NCT06225596
- Locations
- 🇫🇷
Service d'Oncologie Medicale - CHRU Besancon, Besançon, France
🇫🇷Institut Bergonie, Bordeaux Cedex, France
🇫🇷CHU Bordeaux - Hopital Saint-Andre, Bordeaux, France
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Interventions
- Device: Implantable Micro-DeviceDrug: MethotrexateDrug: CarboplatinDrug: AvelumabDrug: PaclitaxelDrug: VinblastineDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: CisplatinDrug: NivolumabDrug: PembrolizumabDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: ErdafitinibDrug: Paclitaxel/Docetaxel/IfosfamideDrug: GemcitabineDrug: Gemcitabine/Carboplatin/NivolumabDrug: EnfortumabDrug: Sacituzumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT05947500
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
SOGUG-AVELUMAB_RWD
- Conditions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 125
- Registration Number
- NCT05700344
- Locations
- 🇪🇸
Hospital Universitario Basurto, Bilbao, Spain
🇪🇸Complejo Hospitalario Torrecárdenas, Almería, Spain
🇪🇸Hospital Universitario de Burgos, Burgos, Spain
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 29
- Registration Number
- NCT05687721
- Locations
- 🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 171
- Registration Number
- NCT05650164
- Locations
- 🇯🇵
Osaka University Hospital, Suita-city, Osaka, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Kindai University Hospital, Osakasayama, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.